Korro Bio, Inc. announced its financial results for the year ended December 31, 2025, highlighting a net loss of $117.3 million, driven by impairment charges. The company also reported an oversubscribed $85 million private placement, extending its cash runway into 2028.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.